CXCR4 and prostate carcinoma: Resveratrol and its combination with AMD3100 as a CXCR4 inhibitor significantly inhibited dihydrotestosterone (DHT)-induced progression of prostate cancer cell line via affecting the CXCR4 pathway [69].